The cost of a combination Anti-Retroviral Therapy (cART) optimization pathway as maintenance therapy in HIV-1 infected patients
DOI:
https://doi.org/10.7175/fe.v18i1.1325Keywords:
Combination Anti-Retroviral Therapy – cART, HIV-1, Italian National Health SystemAbstract
BACKGROUND: In order to reduce/prevent combination Anti-Retroviral Therapy (cART)-related toxicity, while maintaining its therapeutic effectiveness over time, the optimization of the antiretroviral therapy could be performed.AIM: To estimate the economic impact on the Italian National Health Service (NHS) of a cART optimization pathway as maintenance therapy in HIV-1 infected patients over one-year period.
METHODS: Patient data were retrieved from the electronic medical record system in use (year 2015) in a reference HIV Center in Northern Italy. The analysis considered naïve patients and non-naïve patients. To estimate the actual ART expenditure charged to the Center we calculated the cost of cART received during 12 months for each patient. Subsequently, referring to the same patients, a "potential" cART expenditure was estimated. This potential expenditure was estimated taking in consideration the adoption of a specific optimization pathway aimed at maintaining over the time the cART efficacy. Lastly, to assess the sustainability of the optimization pathway, we compared the actual cART expenditure with the potential one. We considered only drug costs (ex-factory prices, included all discounts and VAT) from the perspective of the Italian NHS.
RESULTS: In the 2015, the total expenditure for 564 enrolled HIV-1 patients treated with cART was € 4,042,983. The mean treatment cost per patient was € 7,168. If the Center adopted a specific optimization pathway, the total expenditure would be € 3,914,855 (€ -128,128).
CONCLUSIONS: From the Italian NHS’s perspective, the adoption of a specific cART optimization pathway represents a cost-saving option as maintenance antiretroviral therapy in HIV-1 infected patients.
References
Ministero della Salute – SIMIT. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. November 2016. Available at http://www.salute.gov.it/imgs/C_17_pubblicazioni_2545_allegato.pdf (last accessed April 2017)
Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother 2006; 58: 235-42; https://doi.org/10.1093/jac/dkl191
Margolis AM, Heverling H, Pham PA, et al. A Review of the Toxicity of HIV Medications. J Med Toxicol 2014; 10: 26-39; https://doi.org/10.1007/s13181-013-0325-8
Ravasio R, Rigo F, Lattuada E, et al. Economic evaluation of nevirapine plus raltegravir as maintenance antiretroviral therapy in virologically suppressed HIV-1 infected patients. GRHTA 2016; 3: 110-4
Reliquet V, Chirouze C, Allavena C, et al. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients. Antivir Ther 2014; 19: 117-23; https://doi.org/10.3851/IMP2691
Calcagno C, Montrucchio A, Capetti G, et al. Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy inHIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. Curr HIV Res 2016; 14: 54-60
Friis-Møller N, Ryom L, Smith C, et al.; D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol 2016; 23: 214-23; https://doi.org/10.1177/2047487315579291
Angeletti C, Pezzotti P, Antinori A, et al. Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start. HIV Med 2014; 15: 165-74; https://doi.org/10.1111/hiv.12097
Restelli U, Andreoni M, Antinori A, et al. Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service. Clinicoecon Outcomes Res 2014; 6: 409-14; https://doi.org/10.2147/CEOR.S68101
Restelli U, Fabbiani M, Di Giambenedetto S, et al. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. Clinicoecon Outcomes Res 2017; 9: 173-9; https://doi.org/10.2147/CEOR.S127097
Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naïve subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses 2013; 29: 256-65
Nozza S, Galli L, Antinori A, et al. Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTIs-sparing regimen for naïve patients: preliminary 48-weeks results. In Abstracts of the 6th International AIDS Society, Rome, Italy, 2011, July 17-20. Abstract CDB325.
Calcagno A, Nozza S, Gonzalez de Requena D, et al. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatmentnaïve patients. J Antimicrob Chemother 2013; 68: 1686-8; https://doi.org/10.1093/jac/dkt074
Boyd MA, Kumarasamy N, Moore CL, et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013; 381: 2091-9; https://doi.org/10.1016/S0140-6736(13)61164-2
Reliquet V, Allavena C, Morineau-Le Houssine P, et al. Twelve-year experience of nevirapina use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients. HIV Clin Trials 2010; 11: 110–7; https://doi.org/10.1310/hct1102-110
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
